Susan B. Zolla-pazner - Infectious Diseases

Author Information

Susan B. Zolla-Pazner is a prominent researcher in the field of infectious diseases, currently affiliated with the Department of Medicine, Division of Infectious Diseases at the Icahn School of Medicine at Mount Sinai, New York. Her work has significantly contributed to the understanding and treatment of infectious diseases, particularly focusing on HIV and SARS-CoV-2.

Research Contributions

Throughout her career, Susan B. Zolla-Pazner has made substantial contributions to the field of infectious diseases through her extensive research on HIV and SARS-CoV-2. Her recent works include studies on immune responses and vaccine efficacy, such as the impact of HIV-1 Vpu on Fc-mediated effector functions and the comparison of antibody responses induced by natural infection versus mRNA vaccines. Her research not only advances the scientific understanding of these viruses but also informs clinical practices and public health strategies.

Aliases

Susan B. Zolla-Pazner is also known by various aliases including Susan Zolla-Pazner, Susan B Zolla-Pazner, and S Zolla-Pazner. These variations are commonly found in academic publications and databases.

Publication and Citation Metrics

Metric	Value
Citation Count	24,200
H-Index	84
Paper Count	396

Publications:

HIV-1 Vpu restricts Fc-mediated effector functions in vivo

DOI: 10.1101/2022.02.21.481308

Year: 2022

Differential V2-directed antibody responses in non-human primates infected with SHIVs or immunized with diverse HIV vaccines

DOI: 10.1038/s41467-022-28450-1

Year: 2022

The IgA in milk induced by SARS-CoV-2 infection is comprised of mainly secretory antibody that is neutralizing and highly durable over time

DOI: 10.1371/journal.pone.0249723

Year: 2022

A tale of four studies: HIV vaccine immunogenicity and efficacy in clinical trials.

DOI: 10.1016/S2352-3018(21)00073-4

Year: 2021

Detection of Antibody Responses against SARS-CoV-2 in Plasma and Saliva from Vaccinated and Infected Individuals

DOI: 10.1101/2021.05.11.21256972

Year: 2021

Quantifying Absolute Neutralization Titers against SARS-CoV-2 by a Standardized Virus Neutralization Assay Allows for Cross-Cohort Comparisons of COVID-19 Sera

DOI: 10.1128/mBio.02492-20

Year: 2021

SARS-CoV-2 mRNA vaccines induce a greater array of spike-specific antibody isotypes with more potent complement binding capacity than natural infection

DOI: 10.1101/2021.05.11.21256972

Year: 2021

Detection of Antibody Responses Against SARS-CoV-2 in Plasma and Saliva From Vaccinated and Infected Individuals

DOI: 10.3389/fimmu.2021.759688

Year: 2021

Extended antibody-framework-to-antigen distance observed exclusively with broad HIV-1-neutralizing antibodies recognizing glycan-dense surfaces

DOI: 10.1038/s41467-021-26579-z

Year: 2021

Safety of administering biologics to IBD patients at an outpatient infusion center In New York City during the COVID-19 pandemic: Sars-CoV-2 seroprevalence and clinical and social characteristics

DOI: 10.1101/2021.03.15.21253615

Year: 2021

What are Future Directions for Schistosomiasis Research?

What Are the Symptoms of These Diseases?

How is Chlamydia Transmitted?

What Are the Considerations for Treating Parasitic Infections?

What are the Key Components of Infectious Disease Education?

What is Cervical Cancer?

How Can Transmission Be Prevented?

How Can E. Coli Infections be Prevented?

What Illnesses Do Adenoviruses Cause?

How is Salmonella Diagnosed?

Partnered Content Networks

Relevant Topics